Pivotal Phase 3 Trial for Candel's CAN-2409 Kicks Off in Advanced Lung Cancer
CADL has more than doubled off its 52-week low of $4.35.
Summary
Candel Therapeutics has initiated the global pivotal Phase 3 AURORA trial for its lead immunotherapy candidate, CAN-2409, in advanced non-small cell lung cancer (NSCLC) patients who have not responded to prior immune checkpoint inhibitors. This is a significant expansion for CAN-2409, which recently demonstrated highly positive extended Phase 3 data in prostate cancer. The trial addresses a substantial unmet medical need, as patients with NSCLC who fail current therapies face limited options and poor survival outcomes. The company's strong cash position, reported in Q1 2026, provides financial support for this global pivotal study.
At the time of this announcement, CADL was trading at $10.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $759.1M. The 52-week trading range was $4.35 to $10.38. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.